

**How blood group A might be a risk and blood group O be protected from SARS-CoV-2 (COVID-19) infections (how the virus invades the human body via ABO(H) blood group carbohydrates).**

Peter Arend <sup>a, b, c, 1\*</sup>

**ORCID ID:** <https://orcid.org/0000-0002-4000-4167>

a) Philipps University Marburg, Department of Medicine, D-355, Marburg, Lahn, Germany

b) Gastroenterology Research Laboratory, University of Iowa, College of Medicine, Iowa City, IA, USA

c) Research Laboratories, Chemie Grünenthal GmbH, D-52062 Aachen, Germany.

**Correspondence** to: Dr. Peter Arend,  
Am Oberen Stötchen 14, 57462 Olpe, Germany.  
E-Mail: [parend@t-online.de](mailto:parend@t-online.de)

\* 1 where the experiments of the author were performed.

**Abstract.**

While the angiotensin-converting-enzyme 2 (ACE2) is defined as the primary SARS-CoV-2 receptor (Severe acute respiratory syndrome-related coronavirus), the virus-encoded serine molecule, mobilized by the host's TMPRSS2 (transmembrane protease serine subtype 2) from the viral (S) spike protein, hijacks the N-acetyl-D-galactosamine (GalNAc) metabolism of the host, and the resulting hybrid, serologically A-like/Tn (T-nouvelle) structure may perform the adhesion of the virus to host cells. In humans, this intermediate structure will hypothetically be replaced by ABO(H) blood group-specific, mucin-type, in the case of infection hybrid epitopes, implicating the phenotypically glycosidic accommodation of plasma proteins. The virus may, mimicking the synthetic pathways of the ABO(H) blood groups, bind to the cell surfaces of the blood group O(H) by formation of a hybrid H-type antigen, which does not affect the highly anti-glycan aggressive anti-A and anti-B isoagglutinin activities, exerted by the germline-encoded nonimmune immunoglobulin M (IgM). In the non-O blood groups, developing on the H-precursor, these activities are downregulated by phenotypic glycosylation, while the formation of adaptive immunoglobulin G (IgG) is precluded by clonal selection. The non-O blood groups thus become a preferred target for the virus, whereas blood group O(H) individuals, lacking the A/B phenotype-determining enzymes, have the least molecular contact with the virus; they maintain the critical anti-A and anti-B isoagglutinins and the power of ancestral IgM, considered the humoral spearhead of innate immunity. However, blood group O individuals for an unknown period of time remain pathogen carriers and might belong to the main drivers of SARS-CoV-2 pandemic.

**Keywords:** COVID-19; SARS-CoV-2- human carbohydrate interaction, trans-species glycosylation; A-like/Tn formation, glycan trans-species bridge.

## **Introduction.**

Infection does not mean disease because the invasion of a pathogen does not always lead to symptoms. This phenomenon results from the different qualities and degrees of the physical and chemical bonding types between host and pathogen and reflects the actions of the host's phenotype-determining enzymes, while the presence of asymptomatic carriers is considered the main driver of a pandemic, which undermines its control. The molecular biology of an infection pathogenesis determines the susceptibility of a species to the infection, while the development of symptoms or the severity of the subsequent disease depends on the phenotype. In the case that *O*-glycosylation plays a key role in the pathogenesis of coronavirus diseases, as was discussed already 14 years ago in SARS-CoV-1 infection<sup>1</sup> and is currently again predicted for SARS-CoV-2 or COVID-19,<sup>2</sup> this would implicate the formation of hybrid, serologically A-like, *O*-GalNAc $\alpha$ 1-Ser/Thr-R, Tn antigenic structures. This prediction may not be consistent with the concept of Guillon *et al.* (2008),<sup>3</sup> according to which viruses bind to hosts by *N*-glycosylations when in their study on SARS-CoV-1 infection the interaction between the viral spike protein and the host's cellular receptor was inhibited by natural and monoclonal anti-A antibodies. However, the history of the amino acid serine molecule will show that the host's *O*-glycoproteome plays the key role in SARS-CoV-2 infection pathogenesis. The adhesion of the virus to host cells primarily appears to occur independently of the ABO(H) blood group through the genetically undefined intermediate, serologically A-like/Tn evolutionary/developmental structure, which is common to all metazoan growth and/or ontogenetic processes, and which through its hybridized form apparently acts as a host–pathogen functional bridge in different, unrelated infectious diseases.<sup>4,5</sup> In fact, when the angiotensin-converting-enzyme 2 (ACE2) protein is defined as the primary SARS-

CoV-2 receptor, the following data strongly account for an actual binding between host and pathogen via an intermediate hybrid *O*-glycan, dominated by the pathogen's hydrophilic amino acid serine. In the human species this ontogenetic, blood group independent structure may, depending on the phenotype, be elongated and/or replaced by mucin-type blood group-specific, ABO(H) phenotype-determining carbohydrates according to established pathways.<sup>6</sup>

### **How blood group A might be a risk and blood group O be protected from SARS-CoV-2 (COVID-19) infection.**

The coevolution of species drives diversity in animals and plants and contributes to natural selection, while during an infectious disease, a pathogen may complete an incomplete evolutionary/developmental function by utilizing the host cell's machinery.<sup>5</sup> Analysis of related older data suggests that *Plasmodium falciparum* (*P. falciparum*), the pathogen of malaria tropica, cannot survive outside its human host because it is unable to perform the evolutionarily first protein glycosylation or blood group-independent (serologically A-like) *O*-GalNAc $\alpha$ 1-Ser/Thr-R, Tn antigen formation owing to its inability for synthesizing the amino sugar N-acetyl-D-galactosamine (GalNAc).<sup>7, 8, 4</sup>

Although a non-viral pathogenesis cannot be compared to a viral pathogenesis, the following data strongly suggest an invasion of SARS-CoV 2 into the human cell by the formation of an intermediate hybrid *O*-glycan. The virus cannot survive outside of its hosts, and hypothetically utilizes the host cell's machinery via hijacking its A-like/Tn formation by liberation of serine molecules. Similar suggestions have been the subject of the recent review, published by Watanabe et al. (2019).<sup>9</sup> The virus enters the human body through the human ACE2 protein, which is a polyfunctional protein and, among various other functions, represents the binding domain of the SARS-

CoV viruses. In a complex signaling pathway the human ACE2 binds to the spike (S) protein of the virus envelope,<sup>10</sup> and after subsequent cleavage of the ACE-virus S-protein complex by cathepsin L,<sup>11</sup> the virus enters the cell by receptor-mediated endocytosis.<sup>12</sup> Within the ongoing discussion, as to which amino acids dominate the host–pathogen fusion, the most critical molecular step appears to be the mobilization of the viral serine molecule, performed by the host's TMPRSS2 protease.<sup>13, 14</sup>

The history of this hydrophilic amino acid and its obviously essential involvement in SARS-CoV-2 pathogenesis strongly suggest that the binding between pathogen and host occurs by *O*-glycosylation. Although serine-rich repeat proteins (SRRPs) performing the adhesion of different bacteria to host cell carbohydrates via *O*-glycosylation,<sup>15</sup> and the dominance of the *O*-glycoproteome have not been described for a virus infection pathogenesis, a similar mechanism may take place in SARS-CoV pathogenesis. In view of this concept, the observation that the adhesion of the SARS-CoV-2 spike protein to its cellular receptor was inhibited by monoclonal and natural anti-human blood A group antibodies<sup>3</sup> might have evidenced the presence of the classical *O*-GalNAc binding to a serine molecule. Finally, the preferential occurrence of a severe disease in individuals with non-O blood groups demonstrates that the blood group A and B phenotype-determining sugars are the crucial *O*-glycosidic target. Serine residues, preserved on the viral spike protein, may become available through the action of the host's TMPRSS2 protease,<sup>14</sup> while the ACE2 receptor protein, hypothetically codetermined by the ABO(H) phenotype,<sup>16, 17, 18</sup> mediates the ABO(H) glycan transferring enzyme activity, performing a further (blood group-A and/or B-specific mucin-type) hybrid binding. Analogously, the final binding to blood group O(H) cells might occur by mucin-type fucosylation via fucosyltransferases 1 and

2 (FUT1/FUT2) activities and performance of a hybrid H-type antigen involving the physiological loss of innate anti-H,<sup>4, 5</sup> which does not affect the innate and adaptive anti-A and anti-B isoagglutinin levels. (Figures 1 and 2). Again, within the complex molecular pathogenic process, the most critical molecular step appears to be the mobilization of the viral serine molecule,<sup>14, 19</sup> which accesses both the host's blood-group independent (ontogenetic) and blood group-specific (A-allelic-encoded) *O*-GalNAc $\alpha$ 1-Ser/Thr-R (Tn) formations, whose evolutionary relationship remains unknown. This means, that although the ACE2 protein is defined as the SARS-CoV-2 virus receptor and mediates the transferring enzyme activities, the actual and/or additional binding between host and pathogen appears to be an intermediate hybrid *O*-glycan.

### **ABO(H) blood group phenotype formation dominates innate immunity.**

Humoral innate immunity or the first line of defense and its complex connection with ABO(H) phenotype formation are considered to play the main role in SARS-CoV-2 infection and severity of the subsequent disease. In contrast to adaptive, environmentally-induced immunoglobulin or B-cell activities, which are controlled by clonal selection, the production of the innate, nonimmune and polyreactive immunoglobulin M (IgM) is not restricted to B cells but spontaneously occurs in murine<sup>20, 21</sup> and human<sup>22</sup> normal and malignant epithelial cells as well. An early ovariectomy of an inbred mouse<sup>23, 24, 25</sup>, revealed that in the mammalian species this IgM molecule is structurally connected with the ancestral A-like/Tn antigen through a complex evolutionary process,<sup>26</sup> and it is considered its complementary protein. Hammerström (1973)<sup>27</sup> showed that ancestral glycans arising during germ cell maturation from *O*-

glycosylations by lower metazoans, such as the snail *Helix pomatia*, are associated with the release of a hexamerically structured anti-A/Tn-complementary hemagglutinating defense protein. Intriguingly, the binding patterns and the capacity of this molluscan protein to bind human blood group A RBCs are strikingly similar to those of the mammalian IgM molecule, giving rise to speculation regarding an evolutionary relationship with the mammalian nonimmune anti-A-reactive IgM molecule.<sup>4</sup> In fact, the production of this molecule cannot be stimulated by environmental A-like antigens; its levels remain unaffected after immunization with microbial A-reactive lipopolysaccharides, and the innate IgM can simply be separated from the adaptive IgM by absorption.<sup>28</sup> In humans, the innate IgM molecule is subject to the phenotypic accommodation of plasma proteins, wherein it is enzymatically tailored to the ABO(H) blood group isoagglutinin specificities. Protein glycosylation is thought to occur intracellularly in the Golgi cisternae. Accordingly, during immunoglobulin secretion, the poorly glycosylated intracellular IgM molecule becomes loaded with L-fucose and D-galactose,<sup>29</sup> which subsequently expressed by the extracellular IgM, might form the basis of phenotypic accommodations. Hypothetically, soluble plasma glycotransferases are involved in this process: blood platelets for example, have been detected as a rich source of both glycosyltransferases and energy-rich sugars and amino sugars that are released from activated platelets to function in the extracellular space.<sup>30 31</sup>

Ultimately, innate immunity develops in evolutionary and molecular connection with ABO(H) blood group phenotype formation, involving both the cell surfaces and plasma proteins in identical glycosylations, which in normal conditions

physiologically precludes a corresponding natural autoreactivity, exerted by the ancestral nonimmune or neonatal IgM.<sup>26</sup> In the case of infections, such as SARS-CoV-2, this principle enables the formation of foreign hybrid structures, and in the human blood group O(H) the nonimmune IgM molecule exerts the highly anti-glycan-aggressive anti-A and B-isoagglutinin activities, involving an adaptive response by immunoglobulin G (IgG) antibodies and attacking any non-complementary hybrid structure formations. In contrast, in the non-O blood groups these activities are phenotypically neutralized through the blood group A and B phenotype-determining glycotransferases, and an adaptive anti-A/B IgG response is precluded by clonal selection.<sup>26</sup> Therefore, the non-O blood group individuals become a preferred target for SARS-CoV-2, which thus hypothetically mimics the ABO(H) phenotype synthetic pathways. The physiological lack of innate anti-A and anti-B antibodies in the non-O blood groups A, B and AB poses the immunological dilemma in these blood groups: on one side, it protects them from self-reactivity against complementary structures, but on the other side, it cannot prevent the formation of hybrid but non-complementary (autoantigenic) targets arising in subsequent pathogenic steps. It is assumed, that in SARS-CoV-2 infection, especially in the non-O blood groups the induction of autoimmune processes might contribute to the development of severe disease, which is most likely even dominated by autoimmune inflammations. The proposed relationships between the degree of phenotype diversity and the presence of humoral innate and adaptive responses is illustrated in Figure 1.

# Syngeneic and SARS-CoV-2 hybrid ABO(H) mucin-type formation

## Nonimmune and adaptive humoral response




Figure 1

**Figure 1.**

**The infection is initiated via trans-species blood group-independent, metazoan ontogenetic GalNAc glycosylation or A-like/Tn formation, which in the human is prolonged or replaced by mucin-type ABO(H) blood group-specific formation. Augmenting phenotype diversity is hypothetically associated with decreasing innate immunity: blood group O(H) solely neutralizes the anti-H activity, exerted by the nonimmune IgM but maintains the critical anti-A and an anti-B isoagglutinin activities; it develops the least contact with the pathogen and shows the strongest response. The blood groups A and B maintain the anti-B and anti-A isoagglutinin activities respectively, which does not preclude the formations of foreign antigenic, hybrid structures. Blood group AB develops the strongest contact with the pathogen and shows no response due to phenotypic accommodation of plasma proteins and clonal selection.**

## Conclusions.

The proposed concept of a virus invasion initiated by mobilization of the serine molecule from the viral spike protein and completed by formation of a hybrid, genetically undefined A-like/Tn trans-species molecular bridge, does not question the established functions of the ACE2 receptor protein in its previous<sup>32</sup> and current definitions,<sup>33, 34</sup> but rather shows an additional and more specific interaction between host and pathogen. Both *N*- and *O*-glycosylations may occur within this complex pathogenic process, and among multiple chemical and physico-chemical linkage options, both a trans-species ontogenetic or blood group-independent and blood-group specific binding may be performed through *O*-glycosylations in two different glycosidic steps, dominated by the pathogen's hydrophilic amino acid serine; moreover, a blood group-specific, mucin-type formation appears to elongate and/or replace the trans-species, ontogenetic binding. The prominent evolutionary position of the serine molecule has again been revealed for SARS-CoV-2 infection, and is evident also in other, unrelated infectious diseases, such as malaria tropica, due to the discovery of the serine repeat antigen SERA in malaria tropica,<sup>4, 35, 36, 37</sup> or *Entamoeba histolytica* infection, in which the serine-rich *E. histolytica* protein STREHP<sup>38, 39</sup> dictates the binding and virulence of the parasite.<sup>40</sup> It is proposed that Covid-19 infection is initiated by intermediate hybrid A-like/Tn antigen formation, hijacking the physiological, genetically undefined, serologically A-like/Tn ontogenetic structure, which must be differentiated from the human blood group A-specific epitope (Figure 2). This is encoded by the A allele of the ABO gene located on chromosome 9q34, which together with the B-allele determines the risk of developing life-threatening disease in the non-O blood groups.<sup>5</sup> Interactions between different pathogenic viruses and human ABO(H) glycans have been known for decades, and can be explained by similar

molecular biological models. A human rotavirus interacts with A-type histo-blood group antigen and its infectivity was specifically abrogated by anti-A antibodies.<sup>41</sup> Appropriately, the comprehensive study by Guillon *et al.* (2008),<sup>3</sup> as cited above, and their analysis of a SARS-CoV-1 outbreak in Hongkong in 2003 revealed that blood group O(H) was associated with low risk of infection, while the interaction between the viral spike protein and the host's cellular receptor was inhibited by natural and monoclonal anti-A antibodies *in vitro*. Finally, the actual and first statistical study indicated that people with blood group A have a significantly higher risk for acquiring SARS-CoV-2 or COVID-19 infection, whereas people with blood group O have a significantly lower risk for the infection compared with non-O blood groups.<sup>42</sup> While this observation awaits confirmation, the central immunological position of blood group O(H) might have already become evident in a small study 50 years ago,<sup>43</sup> which has been widely discussed in recent works (Figure 3).<sup>44, 4, 45</sup>

SARS-Cov-2 (COVID-19) infection may be considered an evolutionary selective disease, which will contribute to the present-day world global distribution of the human A and B blood groups that according to Springer a & Wiener (1962)<sup>46</sup> has predominantly arisen in connection with blood group-related life-threatening diseases over millions of years. The synthesis of the blood group AB enables the strongest contact with a pathogen and molecularly precluding any isoagglutinin activity, making this group the least protected and the smallest among the ABO(H) blood groups. In contrast, individuals with blood group O(H), which are prone to many other infections, especially to cholera disease, despite extensive historical cholera pandemics<sup>47, 48, 49</sup> have survived all infectious diseases in an immunological balance with many pathogens as the largest blood group worldwide. These people rarely develop severe disease in blood group A/B-related


infections. In fact, they maintain the anti-A/Tn cross-reactive and anti-B complement-dependent isoagglutinin activities, which are exerted by the polyreactive, nonimmune immunoglobulin M (IgM),<sup>4, 5, 44</sup> regarded as the humoral spearhead of innate immunity and first line of defense. However, during SARS-CoV-2 pandemic a large number of infected people remains asymptomatic, and it might be speculated that especially blood group O individuals for an unknown period of time remain pathogen carriers and belong to the main drivers of the pandemic.



**Figure 2.**

**Complementarity and adhesion of mammalian structures to a pathogen exclude the formation of adaptive and innate antibody activity against the resulting hybrid antigen.<sup>4</sup> The ABO(H) phenotype formation occurs on both the cell surfaces and plasma-proteins.<sup>26</sup> While in the blood group A the naturally-occurring anti-A and anti-H antibody activities, exerted by the polyreactive, nonimmune IgM molecule, are neutralized by the phenotype-determining glycotransferases (FUT1/FUT2 and GalNAc-Ts), the anti-A activities remain unaffected in blood group O(H), which solely neutralizes anti-H. The intermediate A-like/Tn structure has been elongated and/or replaced by mucin-type, blood group O(H) and A-determining epitopes. This figure was constructed according to Figure 2 in a previous article, in which this mechanism may be similarly utilized by a non-viral pathogen, such as the protozoan parasite *Plasmodium falciparum* (See references 4 and 5).**

**Central immunological position and evolutionary  
cross-over point  
of the human histo (blood group) O(H)**



**Figure 3.**

**Figure 3.**

The central immunological position of the blood group O(H) is evident in its comprehensive production of “natural” antibodies against all of the mature A and B glycans and their cross-reactive developmental structures Tn and T. The human A-specific (A-allelic) glycosylation and the trans-species “A-like”/Tn formation are developmentally connected via the formation of cross-reactive anti-A/Tn isoagglutinin. According to Hofmann et al. (2014)<sup>50</sup> blood O(H) sera bind to both Tn and T antigens, and the anti-A isoagglutinin levels in blood group O(H) and blood group B sera are associated with the anti-Tn antibody, which does not react with blood group B red cells or T glycoconjugates. By contrast, the anti-B antibodies of blood group A sera and of blood group O(H) sera bind to B and T glycoconjugates but not to A or Tn glycoconjugates. This selective cross-reactivity of isoagglutinins with Tn and T antigens has been explained by the authors through the phenotype-specific terminal moieties; the terminal N-acetylgalactosamine is shared by A and Tn antigens, and the terminal galactose is, although with a different configuration, shared by B and T antigen. This figure was constructed by Arend (2017)<sup>44</sup> and cited in Arend (2018).<sup>4, 45</sup>

## References.

1. Oostra, M., de Haan, C. A. M., de Groot, R. J. & Rottier, P. J. M. Glycosylation of the Severe Acute Respiratory Syndrome Coronavirus Triple-Spanning Membrane Proteins 3a and M. *J. Virol.* (2006) doi:10.1128/jvi.80.5.2326-2336.2006.
2. Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The proximal origin of SARS-CoV-2. *Nat. Med.* (2020) doi:10.1038/s41591-020-0820-9.
3. Guillon, P. *et al.* Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodies. *Glycobiology* (2008) doi:10.1093/glycob/cwn093.
4. Arend, P. Position of human blood group O(H) and phenotype-determining enzymes in growth and infectious disease. *Annals of the New York Academy of Sciences* (2018) doi:10.1111/nyas.13694.
5. Arend, P. *Malaria tropica evades host immunity through ABO blood group hybridization.* <https://doi.org/10.6084/m9.figshare.8208689.v120> (2020) doi:10.6084/M9.FIGSHARE.8208689.V120.
6. Vitiazeva, V. *et al.* The O-linked glycome and blood group antigens ABO on mucin-type glycoproteins in mucinous and serous epithelial ovarian tumors. *PLoS One* **10**, (2015).
7. Dieckmann-Schuppert A, Bause E, S. R. Studies on O-glycans of Plasmodium-falciparum-infected human erythrocytes. Evidence for O-GlcNAc and O-GlcNAc-transferase in malaria parasites. *Eur. J. Biochem.* **216**, 779–788 (1993).
8. Templeton, T. J. *et al.* Comparative analysis of apicomplexa and genomic diversity in eukaryotes. *Genome Res.* **14**, 1686–

- 1695 (2004).
9. Watanabe, Y., Bowden, T. A., Wilson, I. A. & Crispin, M. Exploitation of glycosylation in enveloped virus pathobiology. *Biochimica et Biophysica Acta - General Subjects* (2019) doi:10.1016/j.bbagen.2019.05.012.
  10. Inoue, Y. *et al.* Clathrin-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus into Target Cells Expressing ACE2 with the Cytoplasmic Tail Deleted. *J. Virol.* (2007) doi:10.1128/jvi.00253-07.
  11. Simmons, G. *et al.* J., Reeves, J. D., Diamond, S. L. & Bates, P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. *Proc. Natl. Acad. Sci. U. S. A.* (2005) doi:10.1073/pnas.0505577102.
  12. Wang, H. *et al.* SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. *Cell Res.* (2008) doi:10.1038/cr.2008.15.
  13. Matsuyama, S. *et al.* Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2. *J. Virol.* (2010) doi:10.1128/jvi.01542-10.
  14. Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* (2020) doi:10.1016/j.cell.2020.02.052.
  15. Latousakis, D., MacKenzie, D. A., Telatin, A. & Juge, N. Serine-rich repeat proteins from gut microbes. *Gut Microbes* (2020) doi:10.1080/19490976.2019.1602428.
  16. Cidl, K., Strelcova, L., Znojil, V. & Vacha, J. Angiotensin I-converting enzyme (ACE) polymorphism and ABO blood groups as factors codetermining plasma ACE activity. *Exp. Hematol.* (1996).

17. Gassó, P., Ritter, M. A., Mas, S. & Lafuente, A. Influence of ABO genotype and phenotype on angiotensin-converting enzyme plasma activity. *JRAAS - J. Renin-Angiotensin-Aldosterone Syst.* (2014) doi:10.1177/1470320313510583.
18. Terao, C. *et al.* Quantitative variation in plasma angiotensin-i converting enzyme activity shows allelic heterogeneity in the ABO blood group locus. *Ann. Hum. Genet.* (2013) doi:10.1111/ahg.12034.
19. Hoffmann, M., Marx, K., Reichl, U., Wuhrer, M. & Rapp, E. Site-specific O-Glycosylation Analysis of Human Blood Plasma Proteins. *Mol. Cell. Proteomics* **15**, 624–641 (2016).
20. Zhou, R., O’Hara, S. P. & Chen, X.-M. MicroRNA regulation of innate immune responses in epithelial cells. *Cell. Mol. Immunol.* **8**, 371–379 (2011).
21. Shao, W. *et al.* Epithelial cells are a source of natural IgM that contribute to innate immune responses. *Int. J. Biochem. Cell Biol.* **73**, 19–29 (2016).
22. Hu, F. *et al.* Spontaneous Production of Immunoglobulin M in Human Epithelial Cancer Cells. *PLoS One* **7**, (2012).
23. Arend, P. & Nijssen, J. Significance of specific ovarian receptors for syngeneic naturally-occurring haemagglutinating anti-A antibodies. *J. Immunogenet.* **3**, 373–82 (1976).
24. Arend, P. & Nijssen, J. Age dependent appearance of A specific ovarian glycolipids and syngeneic ‘natural’ anti A hemolysin in mice. *Zeitschrift fur Immunitatsforsch.* **153**, (1977).
25. AREND, P. & NIJSSEN, J. A-specific autoantigenic ovarian glycolipids inducing production of ‘natural’ anti-A antibody. *Nature* **269**, 255–257 (1977).
26. Arend, P. ABO (histo) blood group phenotype development

- and human reproduction as they relate to ancestral IgM formation: A hypothesis. *Immunobiology* **221**, (2016).
27. Hammarström, S. Binding of Helix Pomatia A Hemagglutinin to Human Erythrocytes and their Cells. Influence of Multivalent Interaction on Affinity. *Scand. J. Immunol.* **2**, 53–66 (1973).
  28. Arend, P. Observations on different origins of ‘naturally-occurring’ antibodies. *Eur J Immunol* **1**, 398–402 (1971).
  29. Andersson J. & Melchers F. Induction of Immunoglobulin M Synthesis and Secretion in Bone-Marrow-Derived Lymphocytes by Locally Concentrated Concanavalin A. *Proc Natl Acad Sci U S A.* **70**, 416–420 (1973).
  30. Wandall, H. H. *et al.* The origin and function of platelet glycosyltransferases. *Blood* (2012) doi:10.1182/blood-2012-02-409235.
  31. Lee-Sundlov, M. M. *et al.* Circulating blood and platelets supply glycosyltransferases that enable extrinsic extracellular glycosylation. *Glycobiology* **27**, 188–198 (2017).
  32. Wu, K. *et al.* A Virus-Binding Hot Spot on Human Angiotensin-Converting Enzyme 2 Is Critical for Binding of Two Different Coronaviruses. *J. Virol.* (2011) doi:10.1128/jvi.02274-10.
  33. Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* (2020) doi:10.1038/s41586-020-2012-7.
  34. Armijos-Jaramillo, V., Yeager, J., Muslin, C. & Perez-Castillo, Y. SARS-CoV-2, an evolutionary perspective of interaction with human ACE2 reveals undiscovered amino acids necessary for complex stability. *bioRxiv* (2020) doi:10.1101/2020.03.21.001933.

35. Bzik, D.J., Li, W.B., Horii, T. and Inselburg, J. Amino acid sequence of the serine-repeat antigen (SERA) of *Plasmodium falciparum* determined from cloned cDNA. *Mol. Biochem. Parasitol.* **30**, 279–288 (1988).
36. Palacpac, N. M. Q., Arisue, N., Tougan, T., Ishii, K. J. & Horii, T. *Plasmodium falciparum* serine repeat antigen 5 (SE36) as a malaria vaccine candidate. *Vaccine* (2011) doi:10.1016/j.vaccine.2011.06.052.
37. Aoki, S. *et al.* Serine repeat antigen (SERA5) is predominantly expressed among the SERA multigene family of *Plasmodium falciparum*, and the acquired antibody titers correlate with serum inhibition of the parasite growth. *J. Biol. Chem.* **277**, 47533–47540 (2002).
38. ZHANG, T., CIESLAK, P. R., FOSTER, L., KUNZ-JENKINS, C. & STANLEY, S. L. Antibodies to the serine rich *Entamoeba histolytica* protein (SREHP) prevent amoebic liver abscess in severe combined immunodeficient (SCID) mice. *Parasite Immunol.* (1994) doi:10.1111/j.1365-3024.1994.tb00344.x.
39. Stanley, S. L., Tian, K., Koester, J. P. & Li, E. The Serine-rich *Entamoeba histolytica* Protein Is a Phosphorylated Membrane Protein Containing *O*-Linked Terminal *N*-Acetylglucosamine Residues. *J. Biol. Chem.* **270**, 4121–4126 (1995).
40. Manochitra K, P. S. In-silico prediction and modeling of the *Entamoeba histolytica* proteins: Serine-rich *Entamoeba histolytica* protein and 29 kDa Cysteine-rich protease. *PeerJ.* **5**, 3160 (2017).
41. Hu, L. *et al.* Cell attachment protein VP8\* of a human rotavirus specifically interacts with A-type histo-blood group

- antigen. *Nature* (2012) doi:10.1038/nature10996.
42. Zhao, J. *et al.* Relationship between the ABO Blood Group and the COVID-19 Susceptibility. *medRxiv* (2020) doi:10.1101/2020.03.11.20031096.
  43. Arend, P. & Fehlhaber, G. Varying influence of increased enteral antigen absorption on the behavior of ‘natural’ antibodies in O and A blood group subjects. Comparative blood group serological studies on patients with ulcerative colitis and healthy persons [Article in German]. *J. Mol. Med. (Klinische Wochenschrift)* **47**, 535–541 (1969).
  44. Arend, P. Early ovariectomy reveals the germline encoding of natural anti-A- and Tn-cross-reactive immunoglobulin M (IgM) arising from developmental O-GalNAc glycosylations. (Germline-encoded natural anti-A/Tn cross-reactive IgM). *Cancer Med.* **6**, (2017).
  45. Arend, P. ABO phenotype-protected reproduction based on human specific  $\alpha$ 1,2 L-fucosylation as explained by the Bombay type formation. *Immunobiology* (2018) doi:https://10.1016/j.imbio.2018.07.015.
  46. Springer, G. F. & Wiener, A. S. Alleged causes of the present-day world distribution of the human abo blood groups. *Nature* (1962) doi:10.1038/193444a0.
  47. Echenberg, M. J. *Africa in the time of cholera: a history of pandemics from 1815 to the present.* *African studies* (2011). doi:10.3201/eid1802.111535.
  48. Mutreja, A. *et al.* Evidence for several waves of global transmission in the seventh cholera pandemic. *Nature* **477**, 462–465 (2011).
  49. Chowdhury, F. R., Nur, Z., Hassan, N., von Seidlein, L. & Dunachie, S. Pandemics, pathogenicity and changing

- molecular epidemiology of cholera in the era of global warming. *Ann Clin Microbiol Antimicrob* **16**, 10 (2017).
50. Hofmann, B. T. *et al.* ABO Blood Group IgM isoagglutinins interact with tumor-associated O-glycan structures in pancreatic cancer. *Clin. Cancer Res.* **20**, 6117–6126 (2014).